A structured summary of a study protocol for a multi-center, randomized controlled trial (RCT) of COVID-19 prevention with Kampo medicines (Integrative Management in Japan for Epidemic Disease by prophylactic study: IMJEDI P1 study)

Takao Namiki(Chiba University), Takashi Ito(Osaka Nishi Clinic), Mosaburo Kainuma(Kyushu University), Hajime Nakae, Tatsuya Nogami(Tokai University), Masaru Mimura(Keio University), Toshiaki Makino(Nagoya City University), Shin Takayama(Tohoku University), Yohei Kawasaki(Japanese Red Cross College of Nursing), Tetsuhiro Yoshino(Keio University Hospital), Yuki Shiko(Chiba University Hospital), Hidetoshi Igari(Chiba University), Kōichiro Tanaka(Kyoto University), Yoshihito Ozawa(Chiba University Hospital), Masahiko Nezu(Chiba University), Tadashi Ishii(Tohoku University Hospital), Ryutaro Arita(Tohoku University Hospital), Juichi Sato(Nagoya University Hospital), Makoto Arai(Tokyo Metropolitan Institute of Medical Science)
Trials
January 6, 2021
Cited by 17


Related Papers